The rational development of biological response modifiers.
Talmadge
J E
JE
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D004337:Drug Carriers; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D007930:Leucine / Q000031:analogs & derivatives / Q000627:therapeutic use; D008081:Liposomes; D010714:Phosphatidylethanolamines / Q000008:administration & dosage; D011994:Recombinant Proteins / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D007155:Immunologic Factors; D016898:Interferon-alpha; D007376:Interleukin-2; D008081:Liposomes; D010714:Phosphatidylethanolamines; D011994:Recombinant Proteins; C037144:mifamurtide; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D007930:Leucine; C012211:ubenimex